Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives

[1]  S. Carmichael,et al.  A Critical Role of Erythropoietin Receptor in Neurogenesis and Post-Stroke Recovery , 2006, The Journal of Neuroscience.

[2]  A. Cerami,et al.  Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.

[3]  M. Wendland,et al.  Erythropoietin Improves Functional and Histological Outcome in Neonatal Stroke , 2005, Pediatric Research.

[4]  G. Karkavelas,et al.  Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia–ischemia in rats , 2005, Brain Research.

[5]  R. Busto,et al.  Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats , 2005, Stroke.

[6]  Changlian Zhu,et al.  The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia‐ischemia as potently as erythropoietin , 2004, Journal of neurochemistry.

[7]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[8]  Ying Wang,et al.  Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats , 2004, Stroke.

[9]  C. Sommer,et al.  Effect of Brain-Derived Neurotrophic Factor Treatment and Forced Arm Use on Functional Motor Recovery After Small Cortical Ischemia , 2004, Stroke.

[10]  P. Ghezzi,et al.  Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis , 2003, The Journal of experimental medicine.

[11]  T. Odergren,et al.  Animal models of stroke: do they have value for discovering neuroprotective agents? , 2003, Trends in pharmacological sciences.

[12]  F. Barone,et al.  Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. , 2003, Current opinion in investigational drugs.

[13]  C. Kessler,et al.  Accelerated Glial Reactivity to Stroke in Aged Rats Correlates with Reduced Functional Recovery , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Lewczuk,et al.  Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.

[16]  Takashi Mori,et al.  Astrocytic Activation and Delayed Infarct Expansion after Permanent Focal Ischemia in Rats. Part II: Suppression of Astrocytic Activation by a Novel Agent (R)-(−)-2-propyloctanoic acid (ONO-2506) Leads to Mitigation of Delayed Infarct Expansion and Early Improvement of Neurologic Deficits , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  C. Kassed,et al.  Neurodegeneration in the rat hippocampus and striatum after middle cerebral artery occlusion , 2002, Brain Research.

[18]  M. Gassmann,et al.  Increased Cerebral Infarct Volumes in Polyglobulic Mice Overexpressing Erythropoietin , 2001, Journal of Cerebral Blood Flow and Metabolism.

[19]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Berry,et al.  Coordination of Fibroblast Growth Factor Receptor 1 (FGFR1) and Fibroblast Growth Factor-2 (FGF-2) Trafficking to Nuclei of Reactive Astrocytes around Cerebral Lesions in Adult Rats , 2001, Molecular and Cellular Neuroscience.

[21]  M. Bernaudin,et al.  Neuroprotection and Angiogenesis: Dual Role of Erythropoietin in Brain Ischemia. , 2000, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[22]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Allegra,et al.  Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. , 2000, European journal of pharmacology.

[24]  E. Mackenzie,et al.  Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse , 2000, Glia.

[25]  J. Mcculloch,et al.  Quantitative Assessment of Ischemic Pathology in Axons, Oligodendrocytes, and Neurons: Attenuation of Damage after Transient Ischemia , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[27]  J. Fawcett,et al.  The glial scar and central nervous system repair , 1999, Brain Research Bulletin.

[28]  J. Mcculloch,et al.  Drug development for stroke: importance of protecting cerebral white matter. , 1999, European journal of pharmacology.

[29]  W. Koroshetz,et al.  Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. , 1999, Stroke.

[30]  S. Masuda,et al.  Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. , 1998, Biochemical and biophysical research communications.

[31]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. K. Malhotra,et al.  Reactive astrocytes: cellular and molecular cues to biological function , 1997, Trends in Neurosciences.

[33]  Michael Chopp,et al.  A rat model of focal embolic cerebral ischemia , 1997, Brain Research.

[34]  William Slikker,et al.  Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration , 1997, Brain Research.

[35]  D. Dewar,et al.  Tau protein is altered by focal cerebral ischaemia in the rat: an immunohistochemical and immunoblotting study , 1995, Brain Research.

[36]  K. Tracey,et al.  Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Hossmann.  Viability thresholds and the penumbra of focal ischemia , 1994, Annals of neurology.

[38]  M. Borgers,et al.  Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. , 1989, Stroke.

[39]  Timothy Schallert,et al.  Seizures and recovery from experimental brain damage , 1988, Experimental Neurology.

[40]  U. Dirnagl,et al.  Inflammation in stroke: the good, the bad, and the unknown. , 2004, Ernst Schering Research Foundation workshop.